NCT07007936View on ClinicalTrials.gov

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Postoperative AnemiaArthroplasty, Replacement, HipArthroplasty, Replacement, Knee
Interventions
DRUG

SSS17 Capsule (6 Dose Levels)

Arm1 ： This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly

DRUG

Placebo Drug

Arm2：placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY